TenSixteen Bio has emerged from stealth aiming to develop drugs for diseases caused by genetic mutations accumulated as we age. The startup has been incubating within Foresite Labs and it now has $40 million to finance its research into this new realm of biology.
As healthcare organizations make progress on their way to the digital transformation of healthcare, choosing a health cloud vendor to support and enable that work should not be taken lightly.
A reportby Chilmark Research sponsored by Innovaccer offers a deep dive into what factors healthcare organizations should consider when evaluating health cloud vendor options.
We are extending our INVEST 2022 Pitch Perfect deadline to Feb 11, 11:59 p.m. ET to allow interested startups to apply to the 4 tracks - PharmaTech, Diagnostics 2.0, Care Coordination and Value-Based Care, and Remote Patient Monitoring and Smart Devices. Slots are going fast so we encourage all startups - particularly those interested to apply in the PharmaTech and Diagnostics tracks to apply immediately. Selected startups will get to pitch LIVE on stage in front of VC judges. Here's the agenda for the INVEST conference.
By Michael Schroeder Thursday, January 27, 2022 7:13 PM
The venture capital firm conducted a 12-month exhaustive search and found no dedicated venture fund for telehealth, Sid Jawahar, its founder and managing partner said. Swiftarc Telehealth will focus initially on obesity care, mental and behavioral health, and pediatrics.
By Andy Miller and Rebecca Grapevine, Georgia Health News Thursday, January 27, 2022 6:41 PM
Georgia lawmakers will consider a bill that could force the state's Medicaid managed-care insurers to repay millions of dollars if their spending on medical care doesn't reach a certain threshold.
By Frank Vinluan Thursday, January 27, 2022 3:03 PM
TenSixteen Bio has emerged from stealth aiming to develop drugs for diseases caused by genetic mutations accumulated as we age. The startup has been incubating within Foresite Labs and it now has $40 million to finance its research into this new realm of biology.
By David Fields Thursday, January 27, 2022 2:30 PM
The current landscape heading into 2022 will keep pharmacy benefits under the microscope. Plan sponsors will evaluate their PBM's pricing model to determine if their contract will deliver predictable costs, more opportunities for increased savings and improved care for their members.
Palliative care must be the standard of care for all who have been diagnosed with progressive, advanced, and terminal illnesses. Never should we hear the phrase, "I'm sorry, there's nothing more I can do," when physicians encounter the failure of a curative course of therapy.
No comments